Natural and synthetic compounds such as trimethoprim behave as inhibitors of efflux in Gram-negative bacteria

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 6, 2010, Pages 1215-1223

  Piddock, Laura J V ^a   Garvey, Mark I ^a   Rahman, M Mukhlesur ^b   Gibbons, Simon ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

AcrAB TolC; Antibiotic resistance; EPIs

Indexed keywords

2 NAPHTHYLAMINE; ACRAB PROTEIN; ADRENALIN; ARECOLINE; ATROPINE; BACTERIAL PROTEIN; CAFFEINE; CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; CATHINONE; CHLORAMPHENICOL; CIPROFLOXACIN; EPHEDRINE; ERGOMETRINE; ERGOTAMINE; ERYTHROMYCIN; ETHIDIUM BROMIDE; HARMALINE; HARMINE; HOE 33342; MORPHINE; NORADRENALIN; NOREPHEDRINE; QUININE; STRYCHNINE; TETRACYCLINE; THEOBROMINE; THEOPHYLLINE; TOLC PROTEIN; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BIOASSAY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG STRUCTURE; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; HYPOTHESIS; INHIBITION KINETICS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; SALMONELLA ENTERICA; SALMONELLA TYPHIMURIUM; SEROTYPE; TRANSPORT KINETICS;

ANTI-BACTERIAL AGENTS; BENZIMIDAZOLES; DRUG SYNERGISM; ENTEROBACTERIACEAE; ENZYME INHIBITORS; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA;

EID: 77953518245     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq079     Document Type: Article

References (32)

1. Taubes G. The bacteria fight back. Science 2008; 321: 356-61.
2. Helms M, Ethelberg S, Mølbak K et al. International Salmonella Typhimurium DT104 infections, 1992-2001. Emerg Infect Dis 2005; 11: 859-67.
3. Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 2006; 19: 382-402.
4. Piddock LJV, Griggs DJ, Hall MC et al. Ciprofloxacin-resistance in clinical isolates of Salmonella typhimurium obtained from two patients. Antimicrob Agents Chemother 1993; 37: 662-6.
5. Ricci V, Piddock LJV. Ciprofloxacin selects for multi-drug resistance in Salmonella enterica serovar Typhimurium mediated by at least two different pathways. J Antimicrob Chemother 2009; 63: 909-16.
6. Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic-a vision for applied use. Biochem Pharmacol 2006; 71: 910-8.
7. Ricci V, Tzakas P, Buckley A et al. Ciprofloxacin-resistant Salmonella enterica serovar Typhimurium strains are difficult to select in the absence of AcrB and TolC. Antimicrob Agents Chemother 2006; 50: 38-42.
8. Webber MA, Randall LP, Cooles S et al. Triclosan resistance in Salmonella enterica serovar Typhimurium. J Antimicrob Chemother 2008; 62: 83-91.
9. Ricci V, Piddock LJV. Only for substrate antibiotics is a functional AcrAB-TolC efflux pump and RamA required to select multidrug resistant Salmonella Typhimurium. J Antimicrob Chemother 2009 64: 654-7.
10. Lomovskaya O, Warren MS, Lee A et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001; 45: 105-16.
11. Piddock LJ. Multidrug-resistance efflux pumps - not just for resistance. Nat Rev Microbiol 2006; 4: 629-36.
12. Bailey AM, Paulsen IT, Piddock LJV. RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine. Antimicrob Agents Chemother 2008; 52: 3604-11.
13. Nargotra A, Koul S, Sharma S et al. Quantitative structure-activity relationship (QSAR) of aryl alkenyl amides/imines for bacterial efflux pump inhibitors. Eur J Med Chem 2009; 44: 229-38.
14. Renau TE, Léger R, Filonova L et al. Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorg Med Chem Lett 2003; 13: 2755-8.
15. Pannek S, Higgins PG, Steinke P et al. Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthyl methyl)-piperazine and phenyl-arginine-β-naphthylamide. J Antimicrob Chemother 2006; 57: 970-4.
16. Schumacher A, Steinke P, Bohnert JA et al. Effect of 1-(1-naphthyl methyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Enterobacteriaceae other than Escherichia coli. J Antimicrob Chemother 2006; 57: 344-8.
17. Kern WV, Steinke P, Schumacher A et al. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli. J Antimicrob Chemother 2006; 57: 339-43.
18. Bohnert JA, Szymaniak-Vits MS, Schuster S et al. Antimicrobial action and efflux pump inhibition by selective serotonin reuptake inhibitors (SSRIs) in Escherichia (E) coli strains over-expressing four different RND efflux pumps. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract E-1457. American Society for Microbiology, Washington, DC, USA.
19. Eaves DJV, Ricci V, Piddock LJV. Expression of acrB, acrF, acrB, marA and soxS in Salmonella enterica serovar Typhimurium: role in multiple antibiotic resistance. Antimicrob Agents Chemother 2004; 48: 1145-50.
20. Buckley A, Webber MA, Cooles S et al. The AcrAB-TolC efflux system of Salmonella enterica serovar Typhimurium plays a role in pathogenesis. Cell Microbiol 2006; 8: 847-56.
21. Webber MA, Bailey AM, Blair JMA et al. The global consequence of disruption of the AcrAB-TolC efflux pump in Salmonella enterica includes reduced expression of SPI-1 and other attributes required to infect the host. J Bacteriol 2009; 191: 4276-85.
22. Piddock LJV, White DG, Gensberg K et al. Evidence for an efflux pump mediating multiple antibiotic resistance in Salmonella enterica serovar Typhimurium. Antimicrob Agents Chemother 2000; 44: 3118-21.
23. Lund ME, Blazevic DJ, Matsen JM. Rapid gentamicin bioassay using a multiple-antibiotic resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 1973; 4: 569-73.
24. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001; 48 Suppl 1: 5-16.
25. Andrews JM. Chapter Two. Determination of Minimum Inhibitory Concentrations. 2006. http://www.bsac.org.uk/susceptibility_testing/guide_to_antimicrobial_susceptibility_testing.cfm (19 January 2010, date last accessed).
26. Gibbons S, Oluwatuyi M, Kaatz GW. A novel inhibitor of multidrug efflux pumps in Staphylococcus aureus. J Antimicrob Chemother 2003; 51:13-7.
27. Bohnert JA, Schuster S, Seeger MA et al. Site-directed mutagenesis reveals putative substrate binding residues in the Escherichia coli RND efflux pump AcrB. J Bacteriol 2008; 190: 8225-9.
28. Leonard SN, Kaatz GW, Rucker LR et al. Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2008; 62: 1305-10.
29. Mandal S, Mandal MD, Pal NK. Synergism of ciprofloxacin and trimethoprim against Salmonella enterica serovar Typhi isolates showing reduced susceptibility to ciprofloxacin. Chemotherapy 2004; 50:152-4.
30. Wray C, Sojka WJ. Experimental Salmonella typhimurium infection in calves. Res Vet Sci 1978; 25: 139-143.
31. Tindall BJ, Grimont PA, Garrity GM et al. Nomenclature and taxonomy of the genus Salmonella. Int J Syst Evol Microbiol 2005; 55: 521-4.
32. Nishino K, Latifi T, Groisman EA. Virulence and drug resistance roles of multidrug efflux systems of Salmonella enterica serovar Typhimurium. Mol Microbiol 2006; 59: 126-41.